Table 2.
Efficacy results
| CRPC | MSS CRC | NSCLC | ||||
|---|---|---|---|---|---|---|
|
Navarixin 30 mg + Pembrolizumab 200 mg n = 20 |
Navarixin 100 mg + Pembrolizumab 200 mg n = 20 |
Navarixin 30 mg + Pembrolizumab 200 mg n = 19 |
Navarixin 100 mg + Pembrolizumab 200 mg n = 21 |
Navarixin 30 mg + Pembrolizumab 200 mg n = 12 |
Navarixin 100 mg + Pembrolizumab 200 mg n = 13 |
|
| Objective response rate, %a | 5 | 5 | 5 | 0 | 0 | 0 |
| Objective response rate for disease state, %a | 5 | 2.5 | 0 | |||
| Best overall response, n (%)a | ||||||
| Complete response | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response | 1 (5) | 1 (5) | 1 (5) | 0 | 0 | 0 |
| Stable disease | 6 (30) | 6 (30) | 2 (11) | 3 (14) | 6 (50) | 3 (23) |
| Progressive disease | 12 (60) | 10 (50) | 15 (79) | 16 (76) | 6 (50) | 8 (62) |
| Nonevaluableb | 0 | 0 | 0 | 1 (5) | 0 | 0 |
| No assessmentc | 1 (5) | 3 (15) | 1 (5) | 1 (5) | 0 | 2 (15) |
| PFSa | ||||||
| Events, n (%) | 19 (95) | 17 (85) | 19 (100) | 21 (100) | 11 (92) | 12 (92) |
| Median (95% CI), mo | 2.1 (1.9‒4.1) | 2.1 (1.9‒4.5) | 1.8 (1.0‒2.0) | 1.9 (1.6‒2.0) | 2.4 (1.6‒10.2) | 2.1 (1.9‒2.4) |
| 6-mo PFS rate (95% CI), % | 16.2 (4.0‒35.5) | 21.5 (6.7‒41.7) | 10.5 (1.8‒28.4) | 4.8 (0.3‒19.7) | 25.0 (6.0‒50.5) | 0 (NR‒NR) |
| OS | ||||||
| Death, n (%) | 18 (90) | 15 (75) | 19 (100) | 20 (95) | 11 (92) | 9 (69) |
| Median (95% CI), mo | 10.8 (7.9‒13.4) | 11.2 (3.7‒23.0) | 6.5 (3.0‒9.7) | 8.0 (5.7‒14.4) | 13.0 (3.2‒18.0) | 12.0 (2.4‒19.9) |
| 6-mo OS rate (95% CI), % | 89.7 (64.8‒97.3) | 55.0 (31.3‒73.5) | 57.9 (33.2‒76.3) | 70.8 (46.2‒85.7) | 75.0 (40.8‒91.2) | 73.3 (37.9‒90.6) |
CRPC, castration-resistant prostate cancer; MSS CRC, microsatellite-stable colorectal cancer; NR, not reached; NSCLC, non–small-cell lung cancer; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors
aPer RECIST version 1.1 as assessed by the investigator
bIncludes patients with (a) no imaging/measurement done at all or only partial lesion measurements done at first time point and subsequent time point; (b) complete response at first time point but with no imaging/measurement done at all or only partial lesion measurements done without meeting the minimum criteria for stable disease duration at subsequent time point; (c) partial response at first time point but with no imaging/measurement done at all or only partial lesion measurements done without meeting the minimum criteria for stable disease duration at subsequent time point
cIncludes patients without postbaseline assessment at the database cutoff date